Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Biogen's Quarterly Earnings Preview: What You Need to Know

Biogen is scheduled to release its fourth-quarter earnings next month, and analysts are forecasting a double-digit increase in its bottom line.

The 5 worst performing stocks on the Nasdaq 100 in 2024

The 5 worst performing stocks on the Nasdaq 100 in 2024

AI was huge in 2024. The underperformers list reflects challenges in the other sectors.

Biogen Stock: Is BIIB Underperforming the Healthcare Sector?

Biogen Stock: Is BIIB Underperforming the Healthcare Sector?

Biogen has recently lagged behind the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on the stock's long-term growth potential.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Analysts Predict These Will Be Next Year's Top 10 Stocks

Missed out on this year's top S&P 500 stocks? Analysts are already offering up their ideas on which stocks will rule in 2025.

Investors Business Daily

Assessing Biogen: Insights From 19 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months.

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

European committee takes a second look at Alzheimer's drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

The Independent UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review

The stock market retreated this week amid earnings from Microsoft, Amazon, Meta, Apple, Google and many more, along with preelection jitters.

Investors Business Daily

Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough.

Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough.

Biogen stock dipped Wednesday despite an unexpected boost from its new Alzheimer's drug, Leqembi, and an earnings guidance hike.

Investors Business Daily

Biogen's Q3 2024 Earnings: What to Expect

Biogen's Q3 2024 Earnings: What to Expect

Biogen will release its third-quarter earnings this month, and analysts anticipate a double-digit profit dip.

What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One

What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One

Bioverativ formed a perfect double bottom, a key chart pattern for growth stock hunters, and broke out ahead of its big 61% gain on news it's being bought by Sanofi.

Investors Business Daily

Is Biogen Stock Underperforming the Dow?

Is Biogen Stock Underperforming the Dow?

Biogen has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

International Business Times

Is Wall Street Bullish or Bearish on Biogen Stock?

Is Wall Street Bullish or Bearish on Biogen Stock?

Despite Biogen’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review

The stock market took a bearish turn amid economic fears. Apple and Meta had strong results, while AI spending remains robust.

Investors Business Daily

Biogen Stock Slips As Alzheimer's Drug Looks Abroad For Quarterly Beat

Biogen stock slipped early Thursday despite a second-quarter beat that included strong of its new Alzheimer's treatment, Leqembi.

Investors Business Daily

Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug

Biogen stock tumbled Friday after European regulators rejected its Eisai-partnered Alzheimer's treatment, citing steep side effects.

Investors Business Daily

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails

Sage Therapeutics said Wednesday its Biogen-partnered treatment for essential tremor failed in a study, leading Sage stock to collapse.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

Ionis Pharmaceuticals stock surged Monday after the company unveiled promising results for a drug that treats a rare genetic condition.

Biogen Earnings Preview: What to Expect

Biogen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

Investors Business Daily

Three Surprising Names That Could Be On Biogen's Buyout Shortlist

Biogen stock has mostly trended sideways this year, but that could soon change with up to $10 billion in dry powder, an analyst said Tuesday.

Investors Business Daily

Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug

Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.

Is Biogen Stock Underperforming the Nasdaq?

Biogen underperforms the Nasdaq Composite, and analysts remain cautiously optimistic about the stock’s prospects.

Investors Business Daily

Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower

Eli Lilly stock seesawed Tuesday after a Food and Drug Administration panel endorsed its Alzheimer's treatment, donanemab.

Investors Business Daily

FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug

Eli Lilly stock jumped Monday after FDA advisors said the benefits of Alzheimer's treatment donanemab outweigh the risks for most patients.

People

Kritika SarmahHer

Patrick Gelsinger

Robert Kelly Ortberg

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

250,046 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play